Tech Company Financing Transactions
Meissa Vaccines Funding Round
Meissa Vaccines secured a $30 million Series A funding round on 9/27/2019. Backers included Morningside Group.
Transaction Overview
Company Name
Announced On
9/27/2019
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series A
Investors
Morningside Group (Stephanie O'Brien)
Proceeds Purpose
The proceeds of the financing will be used to expand the team, conduct Phase 1 and 2 clinical trials for Meissa's investigational vaccine for respiratory syncytial virus (RSV), and support a viral vaccine pipeline based on the company's synthetic biology technology.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1100 Island Dr. 202
Redwood City, CA 94065
USA
Redwood City, CA 94065
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Meissa Vaccines is a start-up pharmaceutical development company focused on the in-licensing and advancement of vaccines for respiratory syncytial virus (RSV, the largest unmet respiratory medical need in pediatrics) and rhinovirus (leading cause of infectious disease worldwide).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Marty Moore
Chief Medical Officer
Karen Slobod
Chief Scientific Officer
Roderick Tang
VP - Operations
Janelle Muranaka
VP - Regulatory Affairs
Fiona Cameron
Browse more venture capital transactions:
Prev: 9/27/2019: Teampay venture capital transaction
Next: 9/27/2019: Paro venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs